$4.54
0.133.07%
Ult. Agg.: Oct 30, 4:59 PM
Entrada Therapeutics (TRDA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.07 | $-1.03 | $-1.22 | $-0.99 |
| Actual | $-1.01 | $-0.95 | $-0.94 | $-1.06 |
| Surprise | +5.61% | +7.77% | +22.9% | -7.07% |
| Revenue | ||||
| Estimate | $2.0M | $3.6M | $5.0M | $7.3M |
| Actual | $898000 | $875000 | $1.3M | $1.6M |
| Surprise | -54.3% | -75.8% | -73.8% | -78.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.99 | $-0.91 | $-0.95 | $-0.85 |
| Revenue | ||||
| Consensus | $5.8M | $10.1M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-1.01 | $-1.07 | 5.61 % |
| Q1 | May 7, 2026 | $-0.95 | $-1.03 | 7.77 % |
| Q4 | Feb 26, 2026 | $-0.94 | $-1.22 | 22.9 % |
| Q3 | Nov 6, 2025 | $-1.06 | $-0.99 | -7.07 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $898.00K | $1.96M | -54.3 % |
| Q1 | May 7, 2026 | $875.00K | $3.61M | -75.8 % |
| Q4 | Feb 26, 2026 | $1.30M | $4.96M | -73.8 % |
| Q3 | Nov 6, 2025 | $1.61M | $7.32M | -78.0 % |